ROYAL BANK OF CANADA - REVANCE THERAPEUTICS INC ownership

REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 199 filers reported holding REVANCE THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.21 and the average weighting 0.1%.

Quarter-by-quarter ownership
ROYAL BANK OF CANADA ownership history of REVANCE THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$73,000
-84.4%
28,442
-70.0%
0.00%
Q1 2024$467,000
-40.6%
94,753
+6.1%
0.00%
Q4 2023$786,000
-5.3%
89,328
+23.6%
0.00%
Q3 2023$830,000
-23.3%
72,263
+69.2%
0.00%
Q2 2023$1,082,000
-23.3%
42,710
-2.5%
0.00%
Q1 2023$1,411,000
+20.0%
43,813
-31.2%
0.00%
Q4 2022$1,176,000
-16.8%
63,692
+21.6%
0.00%
Q3 2022$1,414,000
+39.4%
52,372
-28.7%
0.00%
Q2 2022$1,014,000
-7.9%
73,437
+30.1%
0.00%
Q1 2022$1,101,000
+18.6%
56,464
-0.7%
0.00%
Q4 2021$928,000
-19.9%
56,865
+36.7%
0.00%
Q3 2021$1,158,000
+58.6%
41,584
+69.0%
0.00%
Q2 2021$730,000
-11.4%
24,613
-16.6%
0.00%
Q1 2021$824,000
-25.7%
29,525
-24.6%
0.00%
Q4 2020$1,109,000
+74.4%
39,144
+54.7%
0.00%
Q3 2020$636,000
+7.4%
25,302
+4.5%
0.00%
Q2 2020$592,000
+65.4%
24,222
+0.2%
0.00%
Q1 2020$358,000
-9.4%
24,180
-0.8%
0.00%
Q4 2019$395,000
-2.2%
24,387
-21.4%
0.00%
Q3 2019$404,000
-1.9%
31,045
-2.4%
0.00%
Q2 2019$412,000
-2.4%
31,798
+19.0%
0.00%
Q1 2019$422,000
-13.5%
26,730
+10.3%
0.00%
Q4 2018$488,000
-23.8%
24,229
-5.9%
0.00%
Q3 2018$640,000
-9.1%
25,759
+0.5%
0.00%
Q2 2018$704,000
-13.7%
25,629
-3.3%
0.00%
Q1 2018$816,000
-10.9%
26,496
+3.4%
0.00%
Q4 2017$916,000
+21.6%
25,622
-6.2%
0.00%
Q3 2017$753,000
+20.1%
27,321
+14.9%
0.00%
Q2 2017$627,000
+49.6%
23,768
+18.1%
0.00%
Q1 2017$419,000
-2.3%
20,131
-2.9%
0.00%
Q4 2016$429,000
+35.3%
20,740
+6.2%
0.00%
Q3 2016$317,000
+21.5%
19,535
+1.6%
0.00%
Q2 2016$261,000
-26.1%
19,228
-4.9%
0.00%
Q1 2016$353,000
+65.0%
20,220
+221.6%
0.00%
Q4 2015$214,000
+422.0%
6,287
+352.3%
0.00%
Q3 2015$41,000
-28.1%
1,390
-21.2%
0.00%
Q2 2015$57,000
+338.5%
1,765
+171.5%
0.00%
Q1 2015$13,000
-13.3%
650
-27.9%
0.00%
Q4 2014$15,000
+15.4%
901
+38.6%
0.00%
Q3 2014$13,000
-98.5%
650
-97.5%
0.00%
-100.0%
Q2 2014$888,000
+151.6%
26,125
+133.3%
0.00%
Q1 2014$353,00011,2000.00%
Other shareholders
REVANCE THERAPEUTICS INC shareholders Q4 2023
NameSharesValueWeighting ↓
Essex Woodlands Management, Inc. 4,592,047$121,230,00021.92%
Rhenman & Partners Asset Management AB 220,000$5,808,0000.83%
ArrowMark Colorado Holdings LLC 2,045,862$54,011,0000.67%
Vivo Capital, LLC 77,373$2,043,0000.52%
Ghost Tree Capital, LLC 89,295$2,357,0000.49%
ESSEX INVESTMENT MANAGEMENT CO LLC 124,932$3,298,0000.47%
Polar Capital LLP 1,296,371$34,220,0000.46%
SUFFOLK CAPITAL MANAGEMENT LLC 70,095$1,851,0000.24%
EAM Investors, LLC 33,897$895,0000.15%
PointState Capital LP 438,200$11,568,0000.13%
View complete list of REVANCE THERAPEUTICS INC shareholders